Navigation Links
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Date:9/5/2007

- Phase 2 Median Overall Survival Confirmed and Extended at the 12th World

Conference on Lung Cancer in Seoul -

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC). Picoplatin is currently being studied in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is evaluating overall survival as the primary endpoint and is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Yesterday, Poniard presented updated data from its Phase 2 SCLC trial at the 12th World Conference on Lung Cancer in Seoul, which confirmed and extended a median overall survival of 27 weeks (based on an analysis of 63 patients), which compares favorably to a median survival of approximately 17 to 22 weeks for patients who receive other second-line chemotherapy according to the 2007 National Comprehensive Cancer Network practice guidelines.

"Our receipt of fast track designation is the result of our ongoing communications with the FDA, and has the potential to accelerate the development of picoplatin for the treatment of small cell lung cancer, a difficult-to-treat disease, and a patient population with very limited treatment options," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We are focused on executing our ongoing Phase 3 SPEAR trial to facilitate the expeditious filing of a New Drug Application
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...inence is still the best policy , , ROCHES...w study from Mayo Clinic finds the use of the drug...lic hepatitis, an acute inflammation of the liver ...sults of the study are published in the December i...nal.org/ ). , , VIDEO ALERT: Additional au...
(Date:12/1/2008)... Dec. 1 Vical Incorporat...f a $1.0 million milestone payment from Merck &... a Phase I clinical trial of an investigational pl...cine is based on Vical,s DNA gene delivery technol...tase (hTERT). hTERT is the subject of separate lic...
(Date:11/27/2008)...finds the majority of acute lymphoblastic leukemia...t the time of diagnosis , , MEMPHIS, Tenn.,...St. Jude Children,s Research Hospital have identif...s of children with acute lymphoblastic leukemia (A...ay to designing treatments for ALL relapse in chil...
(Date:11/25/2008)..., Ky., Nov. 25 Kleinert... performed the fifth U.S. hand transplant on Messi...isville,s Jewish Hospital Hand Care Center on Mond...round noon and was completed shortly after 9 p.m. ...//www.newscom.com/cgi-bin/prnh/20081125/DC48555-a ...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3invivodata Captures Symptom Relief Data in Endometriosis Trial 3156 1invivodata Captures Symptom Relief Data in Endometriosis Trial 3156 2Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 3154 1Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 3154 2Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 3154 3Top Insurance Expert Calls on 144 000 Holders of Long Term Care Polices to Protest an Eleventh Hour Conseco Trust 26788 1Top Insurance Expert Calls on 144 000 Holders of Long Term Care Polices to Protest an Eleventh Hour Conseco Trust 26788 2Statewide Gambling Conference Series of Firsts Begins 9 30 08 26786 1Statewide Gambling Conference Series of Firsts Begins 9 30 08 26786 2
...2007 - Neoprobe Corporation,(OTCBB:NEOP), a divers...ascular surgical and diagnostic products, today an...enter Phase 2 clinical,study of its lead clinical ...nnosyl-dextran). Lymphoseek is a proprietary,radio...h handheld,gamma detection devices, such as Neopro...
...stCall/ -- Advanced Life,Sciences Holdings, Inc. ,..., the first of two pivotal Phase 3 clinical trials...f cethromycin, a,novel once-a-day antibiotic, for ...). In the study, cethromycin achieved,non-inferior...al,cure rate compared to Biaxin(R) (clarithromycin...
Other Medicine Technology:Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint 2Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 2Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 4Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 5
(Date:12/1/2008)...ncer Institute,s cancer registry has found that as...d or incomplete radiation treatment following brea...re can lead to worse outcomes. , Dr. Heather Taf...eagues found that among a nationally representativ...tients aged 65 and older, almost 1,300 women exper...
(Date:12/1/2008)...Newswire/ -- The Food Allergy & Anaphylaxis Ne... as its new CEO, replacing Founder Anne Munoz-Furl...gs to FAAN extensive knowledge of anaphylaxis, a s...e past six years, as Senior Director of Marketing,... for all Dey Pharmaceutical products, including Ep...
(Date:12/1/2008)...sful disaster relief campaign , , WASHINGTO...Red Cross is asking people across the nation to he...ays. This holiday season push will put the final t...mpaign for Disaster Relief. Already, the campaign ...September, and the Red Cross hopes to meet its tar...
(Date:12/1/2008)...e Cross Blue Shield of Michigan,provided more tha...nformation,today to Michigan Attorney General Mik...on about Michigan,s individual health insurance ma...n,s individual health insurance market,and escala...,s last-resort,insurance carrier, in its individu...
Breaking Medicine News(10 mins):Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:FAAN Names New CEO 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 3Health News:Blue Cross Blue Shield of Michigan Answers Attorney General 2Health News:Blue Cross Blue Shield of Michigan Answers Attorney General 3
...ch Institute have found in animal models just how ...in accelerating breast cancer . Until this study, ...in breast cancer had not been clearly established,...w findings could lead to a better understanding of...
... ordered an inquiry into the alleged incident of a...eration, an official said Thursday. In April, Di...an section operation under his parents' supervisio...ty Hospital in Manapparai, about 450 km from the s...
... superstar Tom Cruise, Katie Holmes has silenced r...ure in a revealing swimsuit. Hollywood.com repor...early stages of pregnancy after she looked like sh...n Madrid. The couple wed last November and alread...
...rsity Hospital and the French Medical Institute f... Linking Afghan Hospitals to International Medica...tor in Afghanistan, today launched a pioneering Te...o expand healthcare access and delivery across the...
Other Medicine News:Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 3Health News:Roshan Announces Launch of Afghanistan's First Telemedicine Project 2Health News:Roshan Announces Launch of Afghanistan's First Telemedicine Project 3
...ntains 20 titanium clips in the ML and M sizes, an...e designed for introduction and use through all ap...arger sized trocar sleeves with the use of a conve...lier through the trocar sleeve, press the loading ...
...sing male/female interlocking features. This desig...mproved hemostasis., ,By comparison, The Reflex&r...allowing for maximum visibility for precise clip p...direct drive clip feeding system with an audible f...
Insert only, Pilling-Weck small clip size
Insert only, Ethicon, medium clip size
Medicine Products: